ClinicalTrials.gg
CompletedNCT07197996RETRAIN 2Updated Sep 15, 2026

The RETRAIN Trial Phase 2

An interventional study of Intermittent Pneumatic Compression and geko® T3 in Ischaemic Stroke, sponsored by Firstkind Ltd. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Firstkind Ltd (part of Sky Medical Technology) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Ischemic Stroke with a site in United Kingdom — 14 open to participants now, 20 under way, 5 of them phase 3. Ischemic Stroke · United Kingdom.

Enrollment
40th of 55
53 · median 464
Started
2025
with 3 others
No phase
22 of 89
2 open now
Registered
87th of 89
by date

Among the 89 studies in Ischemic Stroke with a site in United Kingdom, this one is the 40th largest by enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2025, is one of 22 with no phase, and was the 87th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

14 of the 89 studies in Ischemic Stroke with a site in United Kingdom are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Ischemic Stroke with a site in United Kingdom, or all of them as a file.
02

Study summary

Ischaemic strokes, caused by a disruption in the brain's blood supply, are the second leading cause of death and disability in the United Kingdom. This single-center prospective randomised study aims to measure cerebral blood flow and oxygen delivery in patients who have recently suffered an ischaemic stroke and are using either the geko® neuromuscular electrostimulation device or an intermittent pneumatic compression (IPC) device as part of their routine clinical care.

The geko® device stimulates a nerve in the lower leg, inducing muscle contractions that enhance blood circulation. The IPC device applies controlled external pressure through compressed air and a pump, cyclically inflating and deflating chambers in a sleeve worn on the leg. This mimics the action of calf muscles to promote blood flow.

The primary objective of this study is to assess the effect of the geko® and IPC devices on cerebral blood flow in stroke patients, specifically during the hyperacute phase (within 36 hours) following an ischaemic stroke. Both devices will be used as part of standard care for VTE prevention. Cerebral blood flow will be measured using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG).

Read the detailed description

This study is a randomised trial at a single centre, comparing brain blood flow and activity patterns when two standard treatments for preventing blood clots (VTE) are used following a stroke.

Who Can Take Part?

Patients will be identified for the study as part of their routine hospital care when they arrive at hospital through the emergency department. To take part they must:

  1. Be 18 years or older
  2. Have had an ischaemic stroke confirmed by a stroke doctor
  3. Be within 36 hours of stroke symptom onset
  4. Be unable to stand or move around
  5. Have had a CT or MRI scan confirming no bleeding in the brain

What Will Happen?

After confirming eligibility and once consent is given, 80 participants will be randomly assigned to one of two groups during the study period:

Group 1 - IPC device Group 2 - geko® device

Both devices are standard treatments for preventing blood clots.

Study Assessments

Brain blood flow will be measured while participants are sitting upright in bed. Each session will include:

5 minutes with the device switched off 5 minutes with the device switched on

These assessments will take place twice a day for two days (a total of 40 minutes) with a pre-assessment preparation (a total of 80 minutes over the two days). Blood pressure, ECG, temperature, and oxygen levels will be continuously monitored. No follow-up is required after the study.

03

Conditions studied

  • Ischaemic Stroke

Browse trials for

Keywords

  • Acute ischemic stroke
  • Neuromuscular electrostimulation
  • Effects on cerebral blood flow
  • Randomised controlled trial
  • Cerebral blood flow measurements
  • Stroke rehabilitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult over 18
  2. Patient with ischaemic stroke diagnosis confirmed by a stroke physician.
  3. Within 36 hours of symptom onset.
  4. Unable to stand or mobilise without assistance.
  5. No intracerebral haemorrhage as ruled out by computerised tomography (CT) or Magnetic Resonance Imaging (MRI) scan.

Exclusion criteria

Exclusion Criteria:

  1. Inability to gain consent from the patient, or a declaration from a Personal Consultee or Nominated Consultee.
  2. Absence of a (TIA).
  3. Clinically apparent deep vein thrombosis at screening
  4. Patient is expected to require palliative care within 14 days
  5. No response to the geko® device i.e. no involuntary rhythmic upward and outward movement of the foot (dorsiflexion) at the maximum tolerable device setting.
  6. for the use of the geko™ device

    • Allergy to hydrogel constituents
  7. Contraindications to IPC

    • Severe peripheral vascular disease
    • Large leg ulcers requiring extensive bandaging (small ulcers or skin breaks with flat coverings are not an exclusion)
    • Severe oedema
    • Leg deformities making appropriate fitting impossible
    • Symptomatic congestive cardiac failure of class IV (symptoms of heart failure at rest, any physical activity causing further discomfort).
  8. Single or double leg amputations.
  9. Participation in any other clinical trial
  10. Patients must not have a current coronavirus (COVID-19) infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Group 1 - IPC device

    IPC sleeves applied bilaterally according to manufacturer's instructions for standard VTE prophylaxis following ischaemic stroke.

    Device: Intermittent Pneumatic Compression

  • Experimental
    Group 2 - geko® device

    The geko® device is a disposable, battery-powered neuromuscular electrostimulation device applied bilaterally to the peroneal nerve at the knee. It delivers low-frequency stimulation to activate the calf and foot muscle pumps, enhancing venous return and microcirculatory blood flow. Devices will be applied according to the manufacturer's instructions for VTE prophylaxis.

    Device: geko® T3

Interventions

  • DeviceIntermittent Pneumatic Compression

    The IPC arm will use the Kendall SCD™ 700 Sequential Compression System, a routinely employed device for VTE prophylaxis in stroke patients. In this study, IPC sleeves will be applied bilaterally to the legs within 36 hours of stroke onset and operated according to the manufacturer's instructions. The intervention is distinguished by its cyclical external leg compression to enhance venous return, and it serves as the comparator to the geko® device for evaluating effects on cerebral blood flow and haemodynamics.

    Also known as: Kendall SCD™ 700 Sequential Compression System

  • Devicegeko® T3

    The geko® T3 device is a small, disposable, battery-powered neuromuscular electrostimulation device manufactured by Firstkind Ltd. In this study, the geko® will be applied bilaterally to the common peroneal nerve at the knee within 36 hours of stroke onset. It delivers transcutaneous electrical stimulation at 1 Hz, producing involuntary rhythmic foot dorsiflexion to activate the calf and foot muscle pumps. The intervention is distinguished from IPC by its mechanism of action (neuromuscular stimulation vs. external compression) and will be evaluated for its impact on cerebral haemodynamics, neurovascular coupling, and dynamic cerebral autoregulation during VTE prophylaxis.

    Also known as: geko® device, neuromuscular electrostimulation

06

What researchers measure

Primary outcomes

  1. Change in Cerebral Blood Flow During Device Use

    Cerebral blood flow (CBF) will be assessed using functional near-infrared spectroscopy (fNIRS) combined with EEG, beat-to-beat blood pressure, and transcutaneous CO₂ monitoring. Measurements will compare baseline (no device) to during active use of either the Intermittent Pneumatic Compression (IPC) device or the geko® T3 device. The primary analysis will evaluate differences in cerebral haemodynamics between the two randomized intervention groups.

    Time frame: Day 1-2 (within 36 hours of stroke onset; measurements taken twice daily for 2 consecutive days)

Secondary outcomes

  1. Change in Neurovascular Coupling During Device Use

    Changes in neurovascular coupling will be assessed using combined functional near-infrared spectroscopy (fNIRS) and EEG during resting state and during active use of the Intermittent Pneumatic Compression (IPC) device or the geko® T3 device.

    Time frame: Day 1-2 (twice daily assessments for 2 consecutive days)

  2. Change in Dynamic Cortical Connectivity During Device Use

    Functional connectivity between cortical regions will be measured using fNIRS+EEG data during intervention (IPC or geko® device) compared to baseline.

    Time frame: Day 1-2 (twice daily assessments for 2 consecutive days)

  3. Incidence of Adverse Events

    Number and type of adverse events observed in participants during and after use of either device.

    Time frame: Up to 2 days from enrolment

  4. Incidence of Serious Adverse Events

    Frequency of serious adverse events, including death, life-threatening illness, permanent impairment, or prolonged hospitalisation

    Time frame: Up to 2 days from enrolment

  5. Incidence of Adverse Device Effects

    Frequency of device-related adverse events such as discomfort, skin irritation, or unexpected physiological responses to device use.

    Time frame: Up to 2 days from enrolment

  6. Incidence of Serious Adverse Device Effects

    Frequency of serious device-related adverse events meeting criteria for seriousness under ISO 14155:2020.

    Time frame: Up to 2 days from enrolment

  7. Incidence of Device Deficiencies

    Frequency and type of device deficiencies (malfunctions, usability issues, or inadequacy of instructions for use) observed during the trial.

    Time frame: Up to 2 days from enrolment

07

Study locations

1 site
  • Countess of Chester Hospital
    Chester, Cheshire CH2 1UL, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the results of this trial (including baseline characteristics, outcome measures, and safety data) will be made available to other researchers upon reasonable request, following publication of the main trial results. Data will be shared through a controlled access process after approval of a research proposal and data sharing agreement. Supporting documents (such as the study protocol and statistical analysis plan) will also be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: De-identified IPD will be available beginning 12 months after publication of the primary results and for a period of up to 5 years thereafter.

Access criteria: Researchers must submit a methodologically sound proposal, which will be reviewed by the sponsor and chief investigator. Access will be granted only after a data sharing agreement is signed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in May 2026, 10 months.

Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 10 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Sep 30, 2025
StartActual
Jul 1, 2025
Primary completionActual
May 26, 2026
CompletionActual
May 26, 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07197996
Lead sponsor
Firstkind Ltd
Collaborators
Innovate UK
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Jul 1, 2025
Primary completion
May 26, 2026
Completion
May 26, 2026
Last update
Sep 15, 2026

Study contacts

Kausik Chatterjee
study director · COUNTESS OF CHESTER HOSPITAL NHS FOUNDATION TRUST

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion